Paweł Surowiak

ORCID: 0000-0002-4241-5197
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Estrogen and related hormone effects
  • Drug Transport and Resistance Mechanisms
  • Ovarian cancer diagnosis and treatment
  • Cancer Cells and Metastasis
  • Trace Elements in Health
  • Chemotherapy-induced cardiotoxicity and mitigation
  • RNA Interference and Gene Delivery
  • Inflammatory mediators and NSAID effects
  • DNA Repair Mechanisms
  • Genomics and Chromatin Dynamics
  • Renal and related cancers
  • Cancer-related Molecular Pathways
  • Protease and Inhibitor Mechanisms
  • Chemotherapy-induced organ toxicity mitigation
  • Virus-based gene therapy research
  • Genetic factors in colorectal cancer
  • Peptidase Inhibition and Analysis
  • Nuclear Structure and Function
  • RNA Research and Splicing
  • Cancer, Lipids, and Metabolism
  • S100 Proteins and Annexins
  • Reproductive System and Pregnancy
  • HER2/EGFR in Cancer Research
  • Cancer Research and Treatments
  • CAR-T cell therapy research

Wroclaw Medical University
2010-2023

Charité - Universitätsmedizin Berlin
2005-2013

Poznan University of Medical Sciences
2003-2012

Lublin Oncology Center
2007-2011

Wroclaw University of Health and Sport Sciences
2003-2009

University of Wrocław
2003-2006

University School of Physical Education in Kraków
2006

Humboldt-Universität zu Berlin
2005

Niepubliczna Wyższa Szkoła Medyczna
2005

The Maria Sklodowska-Curie National Research Institute of Oncology
2005

In the last decade, optimized treatment for non-small cell lung cancer had lead to improved prognosis, but overall survival is still very short. To further understand molecular basis of disease we have identify biomarkers related survival. Here present development an online tool suitable real-time meta-analysis published microarray datasets We searched caBIG, GEO and TCGA repositories samples with gene expression data information. Univariate multivariate Cox regression analysis, Kaplan-Meier...

10.1371/journal.pone.0082241 article EN cc-by PLoS ONE 2013-12-18

Abstract Cancer patients with tumors of similar grading, staging and histogenesis can have markedly different treatment responses to chemotherapy agents. So far, individual markers failed correctly predict resistance against anticancer We tested 30 cancer cell lines for sensitivity 5‐fluorouracil, cisplatin, cyclophosphamide, doxorubicin, etoposide, methotrexate, mitomycin C, mitoxantrone, paclitaxel, topotecan vinblastine at drug concentrations that be systemically achieved in patients. The...

10.1002/ijc.21570 article EN International Journal of Cancer 2005-10-10

Abstract Purpose: Cisplatin resistance is a major obstacle in the treatment of ovarian carcinoma. ABCC2 commonly localized apical cell membranes and could confer cisplatin resistance. Here, we show that can be cytoplasmic membrane as well nuclear various human tissues including carcinoma cells. Experimental Design: For subcellular detection ABCC2, immunohistochemistry was done using 41 Federation Internationale des Gynaecologistes et Obstetristes stage III specimens prepared before with...

10.1158/1078-0432.ccr-06-0564 article EN Clinical Cancer Research 2006-12-01

Betulin and betulinic acid are naturally occurring pentacyclic triterpenes showing cytotoxicity towards a number of cancer cell lines. These compounds can be found in the bark many plants. In this report we have compared cytotoxic activity crude birch extract purified betulin human gastric carcinoma (EPG85-257) pancreatic (EPP85-181) drug-sensitive drug-resistant (daunorubicin mitoxantrone) Our results show significant differences sensitivity between lines depending on compound used, suggest...

10.3390/molecules14041639 article EN cc-by Molecules 2009-04-24

Abstract Introduction Recent reports suggest that expression of the cyclooxygenase 2 (COX-2) enzyme may up-regulate MDR1/P-glycoprotein (MDR1/P-gp), an exponent resistance to cytostatic drugs. The present study aimed at examining relationship between COX-2 and MDR1/P-gp in a group breast cancer cases. Methods Immunohistochemical reactions were performed using monoclonal antibodies against on samples originating from 104 cases primary invasive cancer. Results COX-2-positive shown demonstrate...

10.1186/bcr1313 article EN cc-by Breast Cancer Research 2005-08-25

Estrogen as a potential factor of ovarian carcinogenesis, acts via two nuclear receptors, estrogen receptor alpha (ERα) and beta (ERβ), but the cellular signal pathways involved are not completely clear so far. In this study we have described expression ERα, detected by immunocytochemistry in 11 carcinoma cell lines immunohistochemistry 43 Federation Internationale des Gyneacologistes et Obstetristes stage III specimens prepared before after treatment with cisplatin-based schemes. For...

10.1007/s12253-010-9340-0 article EN cc-by-nc Pathology & Oncology Research 2011-01-05

The brain cancer stem cell (CSC) model describes a small subset of glioma cells as being responsible for tumor initiation, conferring therapy resistance and recurrence. In CSC, the PI3-K/AKT RAS/mitogen activated protein kinase (MAPK) pathways are found to be activated. consequence, human transcription factor YB-1, knowing emergence drug driving adenoviral replication, is phosphorylated With this knowledge, YB-1 was established in past biomarker disease progression prognosis. This study...

10.1186/1479-5876-11-216 article EN cc-by Journal of Translational Medicine 2013-09-18

The membrane cofactor protein, CD46 represents a complement inhibitor, which protects autologous cells from complement-mediated cytotoxicity. On tumor cells, may exhibit the potential to protect them immune responses of host. present study aimed at evaluation prognostic significance expression in breast cancers. analyses were performed on 70 samples cancer. Immunohistochemical reactions paraffin sections studied tumors using monoclonal antibodies directed against CD46. Results...

10.1097/pai.0b013e31821a0be9 article EN Applied immunohistochemistry & molecular morphology 2011-05-26

The study aimed at determining the effect of melatonin on activity protective antioxidative enzymes in heart and lipid peroxidation products course intoxication with doxorubicin (DOX). rats were categorized into four groups, receiving: 0.9% NaCl i.p. (NaCl control); [20 mg/kg body weight (b.w.)] s.c. (control Mel); DOX (2.5 b.w.) i.p.; plus doses as above. All substances administered once a week for consecutive weeks. Homogenates tissue examined activities glutathione peroxidase (GPx),...

10.1034/j.1600-079x.2003.00079.x article EN Journal of Pineal Research 2003-08-22

To date individual markers have failed to correctly predict resistance against anticancer agents in breast cancer. We used gene expression patterns attributable chemotherapy-resistant cells detect potential new biomarkers related anthracycline resistance. One of the genes, PSMB7, was selected for further functional studies and clinical validation.We contrasted profiles four pairs different human tumour cell lines their counterparts resistant doxorubicin. Observed overexpression PSMB7...

10.1038/sj.bjc.6605478 article EN cc-by-nc-sa British Journal of Cancer 2009-12-15

BUBR1 (budding uninhibited by benzimidazole-related 1) represents the component of a controlling complex in mitosis. Defects mitotic control result chromosomal instability and, as result, disturb process. This study was aimed at examining prognostic value linked to expression group patients with breast cancer. We analyzed 98 stage II cancer median follow-up 15 years. Immunohistochemical reactions were performed using monoclonal antibodies against BUBR1. also studied mRNA Kaplan-Meier (KM)...

10.1369/0022155413480148 article EN Journal of Histochemistry & Cytochemistry 2013-02-07

The study aimed at determining levels of metallothionein (MT) and Ki-67 antigen expression in adenocarcinomas large intestine examining relation the with various clinical pathological variables. studies were performed on 81 cases adenocarcinoma. Using immunocytochemistry, expressions MT (positive reaction 73 cases) 79 examined obtained results compared with, i.a., grade (G) tumour depth to which intestinal wall was infiltrated by individual tumours. Patient survival analysis also performed,...

10.14670/hh-18.401 article EN PubMed 2003-04-01

Determination of oestrogen receptor alpha (ER) represents at present the most important predictive factor in breast cancers. Data ours and other authors suggest that promising predictive/prognostic factors may also include pS2, metallothionein (MT) CD24. Present study aimed determining prognostic value immunohistochemical determination ER, MT, CD24 expression sections originating from 104 patients with cancer. An univariate multivariate analysis was performed. Both analyses demonstrated...

10.1038/sj.bjc.6603254 article EN cc-by-nc-sa British Journal of Cancer 2006-08-01

Abstract Bearing in mind the limited success of available treatment modalities for therapy multidrug-resistant tumor cells, alternative and complementary strategies need to be developed. It is known that transcriptional activation genes, such as MDR1 MRP1, which play a major role development phenotype involves Y-box protein YB-1. Thus, YB-1 promising target new therapeutic approaches defeat multidrug resistance. In addition, it has been reported previously an important factor adenoviral...

10.1158/0008-5472.can-05-2339 article EN Cancer Research 2006-07-15

Introduction:Due to frequent diagnosis of ovarian cancer at an advanced clinical stage, in most cases surgical debulking is followed by chemotherapy.The principal cause therapeutic failure involves incomplete surgery and resistance neoplastic cells chemotherapy.A search continues for substances which would overcome treatment and, as a result, increase efficacy the applied treatment.Quercetin represents one more interesting compounds, present subjected several tests. Material methods:Studies...

10.17772/gp/1609 article EN cc-by-nc-nd Ginekologia Polska 2013-01-01

The aim of this study was to examine the expression ERM (ezrin, moesin) and Rho (RhoA, RhoB Cdc42) proteins in breast cancer (BC) patients investigate relationship between sub-cellular localisation these clinicopathological characteristics patient survival. specific distribution ERM/Rho analysed by immunohistochemistry a homogeneous group 85 stage II ductal BC with follow-up 15 years. Enhanced immunoreactivity all found be associated presence lymph node metastases P = 0.047, moesin, 0.038,...

10.1007/s13402-013-0125-9 article EN cc-by Cellular Oncology 2013-02-19
Coming Soon ...